Welcome to our dedicated page for Tonix Pharmaceut SEC filings (Ticker: TNXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tonix Pharmaceuticals Holding Corp. SEC filings document a commercial-stage biotechnology company with Nasdaq-listed common stock and programs spanning CNS disorders, immunology, infectious diseases and rare diseases. Recent Form 8-K reports cover Regulation FD disclosures, selected operating and financial results, capital-structure information, commercial arrangements for TONMYA, and clinical or preclinical updates for programs such as TNX-4800, TNX-1700 and TNX-1900.
The company’s proxy and annual meeting filings describe board elections, shareholder voting results, equity incentive plan approvals, executive compensation matters and other governance subjects. Tonix filings also provide formal records of material events, exhibit-based press releases and presentations, risk-related disclosures, registered securities and public-company reporting obligations.
Tonix Pharmaceuticals Holding Corp. reported that Phase 1 clinical data for its investigational monoclonal antibody TNX-1500 were published in the Journal of Clinical Immunology. In a first-in-human study of 26 healthy adults, single intravenous doses of 3, 10, or 30 mg/kg were generally well tolerated, with no serious adverse events and only mild, transient aphthous ulcers deemed possibly related to TNX-1500.
TNX-1500 significantly suppressed T cell-dependent antibody responses to the KLH antigen, blocking primary responses at all doses and secondary responses at 10 and 30 mg/kg, with about a 70% reduction at 3 mg/kg versus placebo. Pharmacokinetic data showed dose-proportional exposure and terminal half-lives around 34–38 days, supporting monthly dosing. Tonix highlighted that a Phase 2 investigator-initiated study in kidney transplant recipients at Massachusetts General Hospital is expected to begin in the second half of 2026, pending FDA clearance of the IND.
Tonix Pharmaceuticals Holding Corp. ownership update: Point72 group reports beneficial ownership of 1,100,964 shares of Common Stock, representing 6.9% of the class as of the close of business on May 14, 2026. The filing attributes shared voting and dispositive power across Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen.
A footnote states that as of March 31, 2026 the reporting persons may have been deemed to beneficially own 125,414 shares (representing 0.9% as of that date). The statement clarifies that the reporting persons directly own no shares and that Point72 Associates holds the referenced securities.
Tonix Pharmaceuticals reported Phase 1 results for TNX-4800, an investigational long-acting monoclonal antibody designed to prevent Lyme disease. In 44 healthy volunteers, single subcutaneous doses showed a favorable safety profile, mostly mild injection-site reactions, and dose‑proportional pharmacokinetics with a mean half‑life of about 62–69 days. Serum levels were detectable within two days and remained quantifiable for up to 12 months in most participants, with exposure at the highest 10 mg/kg dose under 17% of peak levels seen in rat toxicology. Nonclinical primate data support protective serum thresholds, and modeling underpins a two‑dose regimen. Tonix plans an adaptive Phase 2 field study in 2027, pending FDA agreement, while highlighting approximately $185.5 million in cash and no debt as of March 31, 2026.
Tonix Pharmaceuticals Holding Corp. reporting persons Sirenia Capital Management and Alex Silverstein disclose beneficial ownership of 1,297,470 shares of common stock, representing 8.8% of the class on an as‑converted basis. The percentage "assumes the exercise of the warrants" held by the Sirenia Fund.
The filing cites 14,205,401 shares outstanding as of March 27, 2026 from the issuer's proxy statement and notes that 615,025 shares are issuable upon exercise of warrants included in the reported total.
Tonix Pharmaceuticals Holding Corp. director Richard Newcomb Stillwell received a stock option grant covering 22,700 shares of common stock. The options have an exercise price of $13.28 per share and expire on May 12, 2036. They were granted under the company’s 2026 Stock Incentive Plan and will vest on the earlier of the one-year anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders. After this compensation award, Stillwell holds 22,700 derivative securities linked to common stock directly, with no open-market purchase or sale reported in this filing.
Tonix Pharmaceuticals Holding Corp. director Adeoye Y Olukotun reported receiving a stock option grant covering 22,700 shares of common stock. The option has an exercise price of $13.28 per share and expires on May 12, 2036. It was granted under the company’s 2026 Stock Incentive Plan and vests on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders. Following this grant, Olukotun holds stock options for 22,700 underlying shares directly.
Tonix Pharmaceuticals Holding Corp. director Margaret Smith Bell received a grant of stock options as part of equity compensation. She was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share. The options were granted under the company’s 2026 Stock Incentive Plan and will vest on the earlier of the one-year anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders. Following this award, she holds derivative rights to 22,700 shares through these options, which expire in 2036.
Tonix Pharmaceuticals Holding Corp. director Hunter James Randolph Jr reported receiving a grant of stock options as part of his compensation. He was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share, with no cash paid at grant.
The options were granted under the company’s 2026 Stock Incentive Plan and vest on the earlier of one year from the grant date or the company’s 2027 Annual Meeting of Stockholders. Following this grant, Randolph holds options for 22,700 underlying shares directly.
Tonix Pharmaceuticals Holding Corp. director James Treco received a grant of stock options as part of equity compensation. He was awarded options covering 22,700 shares of common stock at an exercise price of $13.28 per share, expiring in 2036.
The options were granted under the company’s 2026 Stock Incentive Plan and will vest on the earlier of the one-year anniversary of the May 12, 2026 grant date or the company’s 2027 Annual Meeting of Stockholders. Following this award, Treco holds options for 22,700 shares directly.
Tonix Pharmaceuticals Holding Corp. director David L. Grange received a grant of stock options covering 22,700 shares of common stock. The options have an exercise price of $13.28 per share, vest on the earlier of one year from grant or the 2027 annual stockholders meeting, and expire in 2036.